Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

November 3, 2025 Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7...
October 28, 2025 07:45 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and...
October 24, 2025 08:30 ET | Source: Journey Medical Corporation

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory...
October 21, 2025 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout

MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys...
October 20, 2025 08:53 ET | Source: Bleichmar Fonti & Auld

MLTX SECURITIES NEWS: MoonLake Immunotherapeutics (NASDAQ: MLTX) Faces Securities Fraud Allegations after Stock Drops 90% -- Contact BFA Law by December 15 Class Action Deadline

MoonLake Immunotherapeutics investors that lost money on their investment are encouraged to contact BFA Law about their rights.
October 16, 2025 05:00 ET | Source: AiCuris Anti-infective Cures AG

Aicuris Announces Pritelivir Met Primary Endpoint in Immunocompromised Patients with Refractory Herpes Simplex Virus in Phase 3 Pivotal Trial

Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of treatment, compared with standard-of-care (SoC) treatments...
October 07, 2025 05:00 ET | Source: Italfarmaco

New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 World Muscle Society Congress

Long-term treatment with givinostat in boys with Duchenne muscular dystrophy continues to show a favourable safety and tolerability profile Consistent efficacy demonstrated across age groups MILAN,...
October 06, 2025 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

October 6, 2025 Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or “the...
September 25, 2025 02:10 ET | Source: VarmX B.V.

ヴァルムエックス (VarmX)、日本の規制当局である医薬品医療機器総合機構 (PMDA) からリード資産VMX-C001に対する第I相試験免除を取得

ヴァルムエックス (VarmX)、日本の規制当局である医薬品医療機器総合機構 (PMDA) からリード資産VMX-C001に対する第I相試験免除を取得日本の規制当局である医薬品医療機器総合機構 (PMDA)...
September 25, 2025 02:10 ET | Source: VarmX B.V.

VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001

Drug developer VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001, enabling it to go straight to Phase 3 studies in Japan.